SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-08 |
| Reported value | $176,054,067 |
| Positions | 18 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| ACLARIS THERAPEUTICS INC | ACRS | COM | $63,347,750 | 11,975,000 |
| ATEA PHARMACEUTICALS INC | AVIR | COM | $32,328,335 | 6,952,330 |
| ENGENE THERAPEUTICS INC | ENGN | COM *A* | $11,538,941 | 6,669,908 |
| KRAFT HEINZ CO | KHC | COM | $10,983,300 | 465,000 |
| OUTSET MED INC | OM | COM NEW | $10,885,108 | 2,519,701 |
| CARMAX INC | KMX | COM | $9,123,525 | 172,500 |
| TILLYS INC | TLYS | CL A | $9,030,000 | 2,150,000 |
| PMV PHARMACEUTICALS INC | PMVP | COM | $7,142,200 | 5,330,000 |
| INSTIL BIO INC | TIL | COM NEW | $4,964,664 | 645,600 |
| TARGET CORP | TGT | COM | $4,897,875 | 37,500 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.